FDA Among Regulatory Authorities Reeling From Brexit Bombshell
This article was originally published in The Rose Sheet
Commissioner Robert Califf says FDA has no firm plan but will “react to whatever happens” following the UK’s momentous decision to leave the EU. The European Medicines Agency also is taking a wait-and-see approach, while regulated industries brace for potential compliance, R&D and IP challenges in Brexit’s aftermath.
You may also be interested in...
The Trans-Pacific Partnership was high among the Personal Care Products Council’s priorities during its recent Lobby Day on Capitol Hill. The trade group’s Executive VP, Global Affairs Francine Lamoriello discussed the trade deal’s promise with the Rose Sheet while acknowledging the challenges it faces in the current political climate.
Beiersdorf and former owner Bayer are on the verge of settling a proposed class action in California’s Northern District challenging “mineral-based” claims on Coppertone sunscreens that also contain chemical UV filters. However, the parties will have to try again with their proposed terms.
AstraZeneca and Novavax have not filed EUAs for their vaccines, and they never might. The pathway remains viable in the short-term, but as BLAs are approved and supplies are no longer short, the window may close.